

ERN eUROGEN Supporting Partner Agreement: Organisations

v.2024-02-09

Agreement between the European Reference Network (ERN) for Rare Urogenital Diseases and Complex Conditions (ERN eUROGEN) and the International Society for the Study of Bladder Pain Syndrome (ESSIC)

An email was sent to the ERN eUROGEN Strategic Board asking them to vote, and the input of ESSIC as a Supporting Partner was welcomed unanimously by all respondents.

ESSIC is therefore officially recognised by ERN eUROGEN as a Supporting Partner, and ERN eUROGEN affirms its commitment to work in collaboration with ESSIC [and their representative(s)] for the benefit of patients living with rare urogenital diseases and complex conditions, under the leadership of Prof. Wout Feitz and Radboudumc, Nijmegen in The Netherlands.


Terms of collaboration between ERN eUROGEN and ESSIC:

- ERN eUROGEN and ESSIC agree to work in collaboration, where possible, on areas of common strategic interest.
- The agreement is for a 3-year period and will be then re-evaluated for a further 3-year period.
- In conveying their opinions and input, ERN eUROGEN and ESSIC will be respectful of the viewpoints and opinions of others and ensure criticism is constructive, to ensure maintenance of the very high standards of professionalism that ERN eUROGEN adheres to. An open and collaborative debate where all individuals can feel respected and valued is a core principle.
- ESSIC accepts the ERN eUROGEN Governance Statutes and ERN eUROGEN Conflict of Interests (COI) Policy.
- One or more representatives of ESSIC and ERN eUROGEN should meet (virtually or face-to-face) at least twice a year concerning collaboration, expectations, and future directions.
- One representative of ESSIC may attend the annual ERN eUROGEN Strategic Board meeting with no financial compensation by ERN eUROGEN and with no voting rights but an advisory status and informative role.
- A presentation can be given by a ESSIC representative at the annual ERN eUROGEN Strategic Board meeting to describe recent developments, expectations, and future directions.
- A presentation can be given at the annual ESSIC meeting by the ERN eUROGEN HCP Network Coordinator Representative or his Sub-Representative to give an update on ERN eUROGEN activities.
- ERN eUROGEN and ESSIC will collaborate on joint webinars for the ERN eUROGEN webinar programme on areas of mutual interest, for example, Interstitial cystitis/bladder pain syndrome.
- ESSIC members will be invited to collaborate on clinical guidelines and clinical decision support tools development, where relevant and appropriate.
- ERN eUROGEN and ESSIC will disseminate relevant information from each other through their communication channels.
- If ESSIC wishes to terminate the partnership with ERN eUROGEN, due to COI, a difference in direction, or other reasons, they should write to the ERN eUROGEN HCP Network Coordinator Representative explaining the reasons for the termination. The ERN Coordination Team will review this and then send a letter to ESSIC to end the partnership.



- If ERN eUROGEN wishes to terminate the partnership with ESSIC due to COI, difference in direction, or other reasons, after an additional consultation has been offered to exchange views, discuss changes in collaboration, and future options, the ERN eUROGEN Coordination Team will send a letter to ESSIC to end the partnership.

Signed:



Prof. Mauro Cervigni

ESSIC President

Date: 12 February 2024

Signed:



Prof Wout Feitz

ERN eUROGEN HCP Network Coordinator Representative

Date: 9 February 2024